Blood Coagulation

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • A Summary of The 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations. 
  • A cell-based model of coagulation and the role of factor VIIa. 
  • A cell-based model of hemostasis. 
  • A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass. 
  • A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. 
  • A comparative study of crosslinked and noncrosslinked fibrin from the major classes of vertebrates. 
  • A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. 
  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. 
  • A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. 
  • A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. 
  • A prospective, randomized comparison of thromboelastographic coagulation profile in patients receiving lactated Ringer's solution, 6% hetastarch in a balanced-saline vehicle, or 6% hetastarch in saline during major surgery. 
  • A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. 
  • A systematic review of thromboelastography utilization in vascular and endovascular surgery. 
  • Actions of thrombin in the interstitium. 
  • Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. 
  • Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. 
  • Adaptive force sonorheometry for assessment of whole blood coagulation. 
  • Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. 
  • Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. 
  • Age and functional correlations of markers of coagulation and inflammation in the elderly: functional implications of elevated crosslinked fibrin degradation products (D-dimers). 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 
  • Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. 
  • Anaphylactic and anaphylactoid reactions. A review. 
  • Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 
  • Anesthetic considerations for the patient with homocystinuria. 
  • Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. 
  • Anticoagulants. 
  • Anticoagulation Strategies in the Perioperative Period for Lung Transplant. 
  • Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more? 
  • Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. 
  • Anticoagulation management associated with extracorporeal circulation. 
  • Anticoagulation strategies for venous thromboembolism. 
  • Antidote-mediated control of an anticoagulant aptamer in vivo. 
  • Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. 
  • Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. 
  • Antithrombin: anti-inflammatory properties and clinical applications. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? 
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 
  • Antithrombotic therapy: new areas to understand efficacy and bleeding. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. 
  • Applications and future of aptamers that achieve rapid-onset anticoagulation. 
  • Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. 
  • Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII. 
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. 
  • Assays for measuring rivaroxaban: their suitability and limitations. 
  • Association of air pollution sources and aldehydes with biomarkers of blood coagulation, pulmonary inflammation, and systemic oxidative stress. 
  • Atrial Fibrillation in Cancer Patients: Recognizing Gaps in Care. 
  • Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy. 
  • Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. 
  • Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. 
  • Biology of Coagulation and Coagulopathy in Neurologic Surgery. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bleeding and clotting while supported with ECMO: time to move forward. 
  • Bleeding and risk for future cardiovascular events in patients with atrial fibrillation on oral anticoagulation: major bleeding is a major problem. 
  • Bleeding and thrombosis associated with ventricular assist device therapy. 
  • Blocking the initiation of coagulation by RNA aptamers to factor VIIa. 
  • Blood coagulation and idiopathic thromboembolism among fertile women. 
  • Blood coagulation: hemostasis and thrombin regulation. 
  • Bovine thrombin: history, use, and risk in the surgical patient. 
  • COVID-19 and its implications for thrombosis and anticoagulation. 
  • Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. 
  • Cell-based models of coagulation: a paradigm in evolution. 
  • Cellular interactions in hemostasis. 
  • Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. 
  • Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Changes in the haemostatic profile during magnesium deficiency in swine. 
  • Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. 
  • Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. 
  • Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Coagulation 2006: a modern view of hemostasis. 
  • Coagulation Conundrum: an Exercise in Clinical Reasoning. 
  • Coagulation abnormalities and thrombosis in patients with COVID-19. 
  • Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. 
  • Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. 
  • Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. 
  • Coagulation changes in elective surgery and trauma. 
  • Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. 
  • Coagulation in Liver Disease. 
  • Coagulation-induced resistance to fluid flow in small-diameter vascular grafts and graft mimics measured by purging pressure. 
  • Coagulopathy Characterized by Rotational Thromboelastometry in a Porcine Pediatric ECMO Model. 
  • Coagulopathy in COVID-19. 
  • Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model. 
  • Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital. 
  • Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures. 
  • Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 
  • Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing. 
  • Controlled Multifactorial Coagulopathy: Effects of Dilution, Hypothermia, and Acidosis on Thrombin Generation In Vitro. 
  • Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. 
  • Cross-linking of fibrin by fibrin=stabilizing factor. 
  • Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. 
  • Damage- and pathogen-associated molecular patterns play differential roles in late mortality after critical illness. 
  • Decellularized tissue-engineered blood vessel as an arterial conduit. 
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. 
  • Derangement of the endothelial glycocalyx in sepsis. 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. 
  • Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. 
  • Developing aptamers into therapeutics. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. 
  • Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Direct oral anticoagulants: new drugs and new concepts. 
  • Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. 
  • Direct thrombin inhibitors. 
  • Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. 
  • Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. 
  • Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery. 
  • Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. 
  • Editor's page: fundamentals in neurocardiology: the brain-platelet-coronary artery interface. 
  • Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction. 
  • Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effect of colistin on phospholipid-based activated partial thromboplastin time clotting assay results in patients receiving concomitant heparin therapy. 
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. 
  • Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. 
  • Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. 
  • Effects of blood storage age on immune, coagulation, and nitric oxide parameters in transfused patients undergoing cardiac surgery. 
  • Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review. 
  • Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. 
  • Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency. 
  • Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. 
  • Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. 
  • Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. 
  • Elimination of predilection sites for thrombus formation in the total artificial heart--before and after. 
  • Emergence of factor IXa as a target for pharmacologic inhibition: editors page. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Ethyl pyruvate prevents inflammatory responses and organ damage during resuscitation in porcine hemorrhage. 
  • Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. 
  • Exposure to concentrated coarse air pollution particles causes mild cardiopulmonary effects in healthy young adults. 
  • Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. 
  • Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. 
  • Extrinsic pathway proteolytic activity. 
  • Factor IXa inhibitors as novel anticoagulants. 
  • Factor concentrates for perioperative bleeding: old drugs with new approaches. 
  • Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. 
  • Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. 
  • Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. 
  • Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. 
  • Failure to visualize experimentally produced emboli and thrombi using 131I streptokinase. 
  • Fathers of modern coagulation. 
  • Fibrinolysis vs disseminated intravascular coagulation. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • Foreword: The Prevention and Management of Thrombosis in Obstetrics and Gynecology. 
  • Functional maturity of the coagulation system in children: an evaluation using thrombelastography. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. 
  • Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. 
  • Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples. 
  • Generation of species cross-reactive aptamers using "toggle" SELEX. 
  • Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. 
  • Glassfrogs conceal blood in their liver to maintain transparency. 
  • Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Heart regeneration in zebrafish. 
  • Hematologic changes occurring with cardiac catheterization. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • Hemostasis and thrombosis in older adults. 
  • Hemostatic effects of therapeutic plasma exchange: A concise review. 
  • Hemostatic properties of the FVIIa analog NN1731. 
  • Heparin Resistance - Clinical Perspectives and Management Strategies. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. 
  • Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • Higher mortality in pediatric and adult trauma patients with traumatic coagulopathy, using age-adjusted diagnostic criteria. 
  • Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil. 
  • How to manage anticoagulation during extracorporeal membrane oxygenation. 
  • ISTH DIC subcommittee communication on anticoagulation in COVID-19. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal. 
  • Idarucizumab for dabigatran overdose. 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults. 
  • Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. 
  • Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. 
  • Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy. 
  • In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. 
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. 
  • In vitro functional testing of endothelial progenitor cells that overexpress thrombomodulin. 
  • Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. 
  • Increased anticoagulation during cardiopulmonary bypass by aprotinin. 
  • Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis. 
  • Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse". 
  • Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. 
  • Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. 
  • Inhibition of Factor Xa : a potential target for the development of new anticoagulants. 
  • Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. 
  • Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. 
  • Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension? 
  • Is there a precursive, relatively procoagulant-inactive form of normal antihemophilic factor (factor VIII)? 
  • Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis? 
  • Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. 
  • Low dose heparin therapy: in vitro verification of antithrombotic effect. 
  • Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. 
  • Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. 
  • Management of hemostasis in vascular surgery. 
  • Management of surgical hemostasis: systemic agents. 
  • Management of surgical hemostasis: topical agents. 
  • Metabolic requirements of contractile force generation in platelet rich plasma - a rheological study. 
  • Modelling the linkage between influenza infection and cardiovascular events via thrombosis. 
  • Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. 
  • Modulation of the Coagulation Cascade Using Aptamers. 
  • Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. 
  • Multicenter Evaluation of the Quantra QPlus System in Adult Patients Undergoing Major Surgical Procedures. 
  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. 
  • Neuroinflammation after surgery: from mechanisms to therapeutic targets. 
  • New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. 
  • New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • Newer concepts of blood coagulation. 
  • Novel constructs for thrombin inhibition. 
  • Novel oral anticoagulants: implications in the perioperative setting. 
  • Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. 
  • Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. 
  • Nucleic acid scavengers inhibit thrombosis without increasing bleeding. 
  • Optimal imaging of in vitro clot sonothrombolysis by MR-guided focused ultrasound. 
  • Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? 
  • Oral factor Xa inhibitors for the long-term management of ACS. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. 
  • Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. 
  • Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. 
  • Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. 
  • Pediatric Transfusion Algorithms: Coming to a Cardiac Operating Room Near You. 
  • Perioperative coagulation management in the intensive care unit. 
  • Perioperative coagulation management: Evolving strategies. 
  • Perioperative hemostatic management of patients treated with vitamin K antagonists. 
  • Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. 
  • Pharmacology of antiplatelet agents. 
  • Platelet Count and Function during Pediatric Extracorporeal Membrane Oxygenation. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activation in patients with thrombotic thrombocytopenic purpura. 
  • Platelet function and pharmacologic inhibition. 
  • Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. 
  • Point of care devices for assessing bleeding and coagulation in the trauma patient. 
  • Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. 
  • Polyimides as biomaterials: preliminary biocompatibility testing. 
  • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. 
  • Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. 
  • Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. 
  • Practical coagulation for the blood banker. 
  • Practice bulletin no. 123: thromboembolism in pregnancy. 
  • Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 
  • Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. 
  • Prenatal screening for thrombophilia: the background and the approach. 
  • Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. 
  • Procoagulant and platelet aggregating properties of antilymphocyte sera. 
  • Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. 
  • Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. 
  • Prohemostatic treatment in cardiac surgery. 
  • Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. 
  • Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. 
  • Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. 
  • Prothrombin complex concentrates in trauma and perioperative bleeding. 
  • Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot. 
  • Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. 
  • Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. 
  • Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. 
  • Reducing the risk of oral contraceptive-induced thrombosis. 
  • Reduction of echo decorrelation via complex principal component filtering. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Regulation of thrombin activity--pharmacologic and structural aspects. 
  • Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. 
  • Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Remodeling the blood coagulation cascade. 
  • Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. 
  • Reply: Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. 
  • Rethinking the coagulation cascade. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? 
  • Review of the biology of bleeding and clotting in the surgical patient. 
  • Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. 
  • Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. 
  • Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation. 
  • Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting. 
  • Safety of warfarin dosing in the intensive care unit following the Fontan procedure. 
  • Safety profile of recombinant factor VIIa. 
  • Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. 
  • Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model. 
  • Sickle cell disease is associated with iron mediated hypercoagulability. 
  • Significance of complement to the mechanism of action of endotoxin. 
  • Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk. 
  • Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. 
  • Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. 
  • Streptokinase-induced degradation of crosslinked and uncrosslinked clots. 
  • Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. 
  • Strong Binding of Platelet Integrin αIIbβ3 to Fibrin Clots: Potential Target to Destabilize Thrombi. 
  • Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. 
  • Sustenance of endothelial cell stability in septic mice through appropriate activation of transient receptor potential vanilloid-4. 
  • Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system. 
  • Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. 
  • TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. 
  • Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy? 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The balance of thrombosis and hemorrhage in surgery. 
  • The cellular basis of traumatic bleeding. 
  • The clotting system - a major player in wound healing. 
  • The coagulation cascade in cirrhosis. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. 
  • The effect of ionised magnesium on coagulation using thromboelastography. 
  • The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. 
  • The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients. 
  • The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. 
  • The effects of cardiopulmonary bypass on coagulation. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. 
  • The immune consequences of trauma. 
  • The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. 
  • The pathogenesis of vascular thrombosis and its impact in microvascular surgery. 
  • The pathology of vitreous hemorrhage. II. Ultrastructure. 
  • The pharmacogenetics of coumarin therapy. 
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2. 
  • The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The role of the membrane in the expression of the vitamin K-dependent enzymes. 
  • The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. 
  • Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. 
  • Thermoelectrical modeling of bipolar coagulation on posterior spinal artery in a porcine spinal surgery model. 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. 
  • Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. 
  • Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. 
  • Thrombosis and cancer: emerging data for the practicing oncologist. 
  • Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. 
  • Tissue factor around dermal vessels has bound factor VII in the absence of injury. 
  • Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Translation and Clinical Development of Antithrombotic Aptamers. 
  • Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. 
  • Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. 
  • Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. 
  • Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. 
  • Up-regulation of tissue factor in human pulmonary artery endothelial cells after ultrafine particle exposure. 
  • Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. 
  • Use of Earlier-Reported Rotational Thromboelastometry Parameters to Evaluate Clotting Status, Fibrinogen, and Platelet Activities in Postpartum Hemorrhage Compared to Surgery and Intensive Care Patients. 
  • Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? 
  • Utility of viscoelastic coagulation testing in liver surgery: a systematic review. 
  • Venous thromboembolism in spine surgery. 
  • What does it take to make the perfect clot? 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Wound healing in hemophilia B mice and low tissue factor mice. 
  • Wound hematoma: prophylaxis with topical thrombin. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics